TY - JOUR
T1 - Use of behavioural activation to manage pain
T2 - a systematic scoping review
AU - Walsh, Sandra
AU - Moseley, G. Lorimer
AU - Gray, Richard John
AU - Gillam, Marianne
AU - Gunn, Kate M.
AU - Barker, Trevor
AU - Tran, Kham
AU - Eshetie, Tesfahun
AU - Jones, Martin
N1 - Funding Information:
Funding This study was supported by infrastructure provided by the Department of Rural Health, University of South Australia. GLM is supported by a Leadership Investigator Grant from the National Health & Medical Research Council of Australia ID1178444.
Publisher Copyright:
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Background Behavioural activation (BA) is an effective treatment for depression; however, it is unclear if it can be used to manage pain. Objectives To conduct a scoping review of primary research that reported using BA to support people living with chronic pain to understand how BA had been used in relation to pain. In addition, we wanted to understand whether there were any reported changes in that pain, and how and who delivered BA. Eligibility criteria Primary research published in English. Sources of evidence We searched seven databases MEDLINE, Ovid Embase, Ovid Emcare, PsycINFO, CINAHL, Scopus and Web of Science, for primary research. No initial date limit was used with the date the searches were conducted used as the end date limit (1 July 2021). Charting methods A customised data extraction table was developed, piloted and used. Results 551 papers were screened for inclusion, with 15 papers included in our review. Studies were conducted in North America and in Canada. These included three case studies, nine uncontrolled trials and three randomised controlled trials. Only two studies reported pain as the primary outcome. BA was applied across a range of pain related conditions. The dose of BA ranged from 3 to 16 sessions. Duration of treatment was 3 weeks to 12 months. Most studies reported reductions in pain following exposure to BA. Conclusion BA has the potential to reduce pain. Caution needs to be exercised in the interpretation of these findings as a high risk of bias was observed in most studies. High-quality research is required to test if BA is an effective intervention for chronic pain.
AB - Background Behavioural activation (BA) is an effective treatment for depression; however, it is unclear if it can be used to manage pain. Objectives To conduct a scoping review of primary research that reported using BA to support people living with chronic pain to understand how BA had been used in relation to pain. In addition, we wanted to understand whether there were any reported changes in that pain, and how and who delivered BA. Eligibility criteria Primary research published in English. Sources of evidence We searched seven databases MEDLINE, Ovid Embase, Ovid Emcare, PsycINFO, CINAHL, Scopus and Web of Science, for primary research. No initial date limit was used with the date the searches were conducted used as the end date limit (1 July 2021). Charting methods A customised data extraction table was developed, piloted and used. Results 551 papers were screened for inclusion, with 15 papers included in our review. Studies were conducted in North America and in Canada. These included three case studies, nine uncontrolled trials and three randomised controlled trials. Only two studies reported pain as the primary outcome. BA was applied across a range of pain related conditions. The dose of BA ranged from 3 to 16 sessions. Duration of treatment was 3 weeks to 12 months. Most studies reported reductions in pain following exposure to BA. Conclusion BA has the potential to reduce pain. Caution needs to be exercised in the interpretation of these findings as a high risk of bias was observed in most studies. High-quality research is required to test if BA is an effective intervention for chronic pain.
KW - pain management
KW - rehabilitation medicine
KW - social medicine
UR - http://www.scopus.com/inward/record.url?scp=85131270910&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2021-056404
DO - 10.1136/bmjopen-2021-056404
M3 - Review article
C2 - 35649614
SN - 2044-6055
VL - 12
SP - e056404
JO - BMJ open
JF - BMJ open
IS - 6
M1 - e056404
ER -